Search





Search





Markets
/
Stocks
/
jnj
/

Johnson & Johnson

JNJ

Add to Watchlist

257.190USD

-0.400-0.16%

Close 08-06 16:00（ET）Quotes delayed by 15 min

618.95BMarket Cap

29.43P/E TTM

Johnson & Johnson

257.190

-0.400-0.16%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-0.16%

5 Days

+0.54%

1 Month

-0.83%

6 Months

+7.17%

Year to Date

+24.28%

1 Year

+50.76%

Key Figures

261.820Open

261.965High

6.93MVolume

29.43P/E TTM

20.07P/E Dynamic

5.200Dividend TTM

0.29%Turnover Ratio

257.590Prev. Close

255.280Low

877.07MTurnover

44.00P/E Static

7.62P/B

2.02%Div Yield TTM

11.17%ROA

251.71052wk High

0.94Volume Ratio

14.07BNet Profit

2.41BShares

8.7382EPS TTM

0.26Beta

27.67%ROE

149.04052wk Low

2.60%Amplitude

68.33%Gross Margin

618.95BMarket Cap

-0.59Reward/Risk

0.98%Risk Rate

TradingKey Stock Score of Johnson & Johnson

Currency: USD Updated: 2026-08-06

Key Insights

Johnson & Johnson's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 267.43.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Johnson & Johnson's Score

Industry at a Glance

Industry Ranking

28 / 156

Overall Ranking

64 / 4276

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

49°C



Very Low

Very High

Positive

Johnson & Johnson Highlights

StrengthsRisks

Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.

Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 94.19B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 84.05%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.05%.

Overvalued

The company’s latest PE is 29.41, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.78B shares, decreasing 3.55% quarter-over-quarter.

Held by Donald Yacktman

Star Investor Donald Yacktman holds 1.31M shares of this stock.

Analyst Rating

Based on 27 analysts

Buy

Current Rating

267.426

Target Price

+4.90%

Upside Space

Johnson & Johnson News

Johnson & Johnson Delivers Bright Q2 Results, Revenue and Profit Both Beat Expectations and Guidance Raised, Pre-Market Shares Fall Against Trend

TradingKey - Global healthcare giant Johnson & Johnson (JNJ) released its second-quarter 2026 earnings report on Wednesday local time. Both revenue and earnings exceeded market expectations, and management further raised its full-year guidance. However, the company's shares fell more than 2% in pre-market trading following the announcement.

TradingKeyWed, Jul 15

What Are Defensive Stocks? Best Defensive Stocks to Buy in 2026

TradingKey - Defensives run on resilience: predictable demand, strong cash flow, conservative balance sheets, and tame volatility. You can’t just look at a sector name to find them. It requires a systematic examination of cash generation, leverage, dividend sustainability, beta, competitive moats, a

TradingKeyMon, Mar 16

China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?

TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).

TradingKeyMon, Dec 8

What Are Defensive Stocks? Should You Buy Them Now? Are Defense Stocks Defensive?

TradingKey - Defensive stocks are seen as "safe havens" during economic downturns because their products or services maintain stable demand regardless of economic cycles. Warren Buffett’s investment success is largely attributed to his preference for defensive blue-chip stocks.

TradingKeyMar 21, 2025

Worried About a Recession? 1 Healthcare Dividend Stock That Has Thrived In Every Market Crash

TradingKey - One of those sectors is healthcare and one of the biggest healthcare companies around is Johnson & Johnson (NYSE: JNJ), a company that also pays a decent dividend to shareholders.

TradingKeyMar 14, 2025

Earnings Forecast

Analyst Rating

Based on 27 analysts

Buy

Current Rating

267.426

Target Price

+4.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

Johnson & Johnson

JNJ

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Pfizer Inc

PFE

AbbVie Inc

ABBV

...

Indicators

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-2.078

Neutral

RSI(14)

52.859

Neutral

STOCH(KDJ)(9,3,3)

26.735

Neutral

ATR(14)

6.286

High Vlolatility

CCI(14)

2.131

Neutral

Williams %R

60.932

Sell

TRIX(12,20)

0.157

Sell

StochRSI(14)

77.852

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

256.052

Buy

MA10

259.769

Sell

MA20

256.532

Buy

MA50

247.168

Buy

MA100

240.152

Buy

MA200

227.717

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Johnson & Johnson Info

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Ticker SymbolJNJ

CompanyJohnson & Johnson

CEODuato (Joaquin Boix)

Websitehttps://www.jnj.com/